Tudor Investment Corp ET AL Increases Holdings in RxSight, Inc. (NASDAQ:RXST)

Tudor Investment Corp ET AL lifted its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 116.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,138 shares of the company's stock after buying an additional 36,669 shares during the quarter. Tudor Investment Corp ET AL owned about 0.17% of RxSight worth $2,343,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Private Trust Co. NA acquired a new stake in RxSight during the 4th quarter worth about $34,000. Coppell Advisory Solutions LLC grew its stake in RxSight by 108.9% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock worth $44,000 after purchasing an additional 672 shares during the period. Arcadia Investment Management Corp MI bought a new stake in RxSight in the fourth quarter worth approximately $46,000. Harbor Investment Advisory LLC acquired a new position in RxSight in the fourth quarter valued at approximately $52,000. Finally, Global Retirement Partners LLC bought a new position in shares of RxSight during the 4th quarter worth approximately $69,000. Institutional investors own 78.78% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RXST. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $17.00 price objective (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Piper Sandler initiated coverage on shares of RxSight in a research report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective on the stock. UBS Group downgraded RxSight from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Bank of America reissued an "underperform" rating and issued a $22.00 price objective (down previously from $36.00) on shares of RxSight in a research note on Thursday, April 3rd. Finally, Wells Fargo & Company cut their target price on RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a report on Thursday, April 3rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, RxSight presently has an average rating of "Hold" and a consensus price target of $37.60.

Insider Buying and Selling

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now owns 24,793 shares in the company, valued at $637,428.03. This trade represents a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.36% of the stock is currently owned by insiders.

RxSight Stock Performance

RXST traded up $0.98 during midday trading on Wednesday, reaching $14.93. The company had a trading volume of 1,524,887 shares, compared to its average volume of 654,947. The business has a 50-day moving average price of $20.09 and a two-hundred day moving average price of $32.14. RxSight, Inc. has a 12-month low of $13.50 and a 12-month high of $66.54. The stock has a market cap of $606.29 million, a PE ratio of -17.98 and a beta of 1.32.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.17). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. On average, research analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current year.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.